Researchers uncover new disease-linked microbial species through pan-body microbiome analysis

Researchers in Germany conducted a pan-body microbiome analysis, uncovering new microbial species and potential therapies linked to diseases, with implications for diagnostic and therapeutic advancements.

FDA Panel Backs Cryoablation in Early Breast Cancer as Alternative to Surgery

An FDA panel on Thursday endorsed a cryoablation system as an alternative to surgery for some early breast cancer patients. By a 9-5 vote, the

November 9, 2024

Immune-Onc’s antibody therapy collects second FDA orphan designation – Pharmaceutical Technology

Share this article IO-202 is a monoclonal antibody that targets leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), which can suppress immunity in solid tumours.

February 22, 2024

FDA accepts Sanofi’s Sarclisa sBLA for priority review

In a Phase III trial, Sanofi’s Sarclisa regimen offered statistically significant PFS improvement in NDMM patients. Credit: Sergiy Palamarchuk/ Shutterstock.com. The US Food and Drug

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.